# Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities

Source: https://onco.cc/trials/nct07572396/  
OnCo record `nct07572396` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of EGCG and Quinine Sulfate Vaginal Suppository in vaginal cancer, run by Amplexd Therapeutics, Inc., now recruiting.

## Summary

Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities is a phase 2 interventional study registered as NCT07572396 by Amplexd Therapeutics, Inc., with 45 participants planned, started 2026-04-30 and due to reach its primary completion in 2026-12-27. Interventions recorded: EGCG and Quinine Sulfate Vaginal Suppository.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07572396
- Phase: 2
- Setting: A Phase II, Randomized, Double-blind, Placebo-Controlled, Proof of Concept Study to Assess the Safety and Efficacy of Dysplasix™ Intravaginally-Administered Suppositories in Patients With High-Risk Human Papillomavirus (Hr-HPV) as Determined by HPV Testing, and Accompanied by Either (1) Atypical Squamous Cells of Undetermined Significance (ASC-US) or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL), as Determined by Cytology
- Sponsor: Amplexd Therapeutics, Inc.
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07572396: https://clinicaltrials.gov/study/NCT07572396

## Connected records

- cancers: [Vaginal cancer](https://onco.cc/cancers/vaginal/)

---
JSON: https://onco.cc/api/v1/entities/nct07572396.json